|

misetionamide (also known as GP-2250) Clinical Trials

1 actively recruiting trial across 1 location

Also known as: gemcitabine

Pipeline

Phase 1: 1

Top Sponsors

  • Persevere Therapeutics Inc.1

Indications

Chicago, Illinois1 trial

A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine

Rush University Medical Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.